Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhen you stop Wegovy, appetite typically returns to its pre-treatment level within days to weeks, and most people gradually regain a significant portion of the weight they lost. Clinical trials show that much of this regain happens within a year of stopping, because semaglutide was suppressing hunger signals that don't disappear permanently. These are prescription-only medicines, and any decision about stopping should be made with the prescriber who knows your full picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The effects of semaglutide on appetite don't vanish the moment you put the pen down. Wegovy has a half-life of roughly one week, so it clears gradually. For the first few weeks after your final dose you may notice hunger creeping back incrementally rather than all at once. That slow return can feel deceptively fine.
The harder part comes later. Data from the STEP 1 trial extension (published in the New England Journal of Medicine and covering 68 weeks on treatment then a further year off it) showed participants regained around 6.9 percentage points of body weight within a year of stopping, recovering roughly two-thirds of what they had lost. For someone who had lost 15 kilograms, that is a meaningful reversal. The STEP 1 trial paper in the NEJM is the clearest source on what actually happens in the period after the medicine stops.
This isn't a failure on the patient's part. Obesity has a strong biological component: the hormonal and neurological signals that drive hunger don't reset permanently during treatment. When the external signal from semaglutide is removed, the underlying biology reasserts itself. If you want to understand what actually happens if you stop Wegovy, from appetite changes through to weight regain, it is worth reading through that before making any decision. The practical timeline matters too. If you're stopping around a holiday, a period of work stress, or a point where your routines are already disrupted, you may want to discuss the timing with your prescriber rather than simply letting the prescription lapse.
For many people, the benefit of Wegovy isn't just the number on the scale. Blood pressure often falls during treatment. Blood sugar and cholesterol profiles improve. Sleep apnoea can become less severe. These changes are largely weight-dependent: as weight returns, those markers tend to follow.
The NHS guidance on weight management injections is clear that these medicines work best alongside sustained dietary and physical-activity changes, precisely because those lifestyle factors give you something to stand on once the medicine stops. If those habits are in place, the reversal can be slower and less complete. If they aren't, the evidence suggests the return to baseline is faster.
This is part of why a good prescriber will want to understand why you are stopping. Side effects that aren't resolving, a planned pregnancy (Wegovy is not recommended in pregnancy or while trying to conceive), changes in health status, or a clinical review decision are all legitimate and different situations. Each changes what stopping looks like and what follow-up is sensible. The same goes for people who have been on treatment for some time and wonder what the longer-term picture after stopping Wegovy actually looks like.
Stopping isn't inherently wrong. NICE's recommendation for semaglutide under TA875 includes a maximum treatment duration of two years within specialist NHS services, which reflects the reality that these are not lifelong licences in every context. Private treatment has no equivalent fixed cap, but most prescribers will want a clinical reason to continue at each review as well as a clinical reason to stop.
If you're considering stopping, the most useful things to have in place are: a realistic picture of what your weight and appetite are likely to do when you stop taking Wegovy, a diet and activity plan that isn't dependent on pharmaceutical appetite suppression, and a follow-up pathway so you're not just left waiting to see what happens. Some people restart treatment after a break if regain is clinically significant. Others transition to a different approach. You can read more about the treatment options available through a private regulated route on the weight management overview.
If your reason for stopping is cost, it is worth being honest with your prescriber about that rather than simply not reordering. A clear explanation of what Wegovy costs privately and what that includes can help you weigh the options, and a prescriber can sometimes discuss whether a dose or schedule change is clinically appropriate.
If you have questions about how the medicine works while you are on it, a plain-language explanation of what Wegovy does during treatment can put the stopping question in context. Our guidance on what happens when you stop using Wegovy covers the practical side of that transition in more detail. And if you're curious whether a different injectable medicine might suit your situation better, our prescribers can discuss that as part of a consultation. Start your free consultation and a GPhC-registered prescriber will review your circumstances the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.